BIOCYTOGEN
Eucure Biopharma, a China-based clinical-stage biotechnology company focused on the development of antibody therapeutics, announced today that it has entered into a collaborative agreement with ISU ABXIS Co., Ltd. (KOSDAQ: 086890), a Korea-based clinical stage company developing immuno-oncology drugs.
Under the terms of the agreement, ISU ABXIS will utilize the sequence of YH003, Biocytogen’s humanized agonistic anti-CD40 antibody currently in phase II clinical trials, to construct a few groups of tri-specific antibodies and develop cancer drugs for multiple indications using its technology platform. Eucure Biopharma will receive an upfront payment, milestone payments and royalties.
“Biocytogen utilized its unique evidence-based in vivo drug screening platform to obtain YH003, which has demonstrated a good preclinical safety and efficacy profile,” said Dr. Rong Chen, Vice President of Biocytogen and CEO/CMO of Eucure Biopharma. “Further, YH003’s phase I clinical trials indicate good tolerability and safety profiles, as well as encouraging antitumor activities against several tumor types, including malignant melanoma and pancreatic cancer.”
“CD40 is a key co-stimulator in adaptive immune responses,” said Yeob Hwang, CEO of ISU ABXIS. “We are glad for the opportunity to utilize Biocytogen/Eucure Biopharma’s anti-CD40 antibody (YH003), as it has outstanding efficacy and safety profiles, both preclinically and clinically. These favorable properties will undoubtedly accelerate our tri-specific antibody development against tumors.”
About YH003
YH003 is a humanized IgG2 agonistic CD40 antibody. Whether used as a single agent or in combination with anti-PD-1 monoclonal antibody drugs, YH003 demonstrated strong anti-tumor effects against multiple tumor models in Biocytogen’s humanized CD40 mice, without exhibiting hepatotoxicity or other toxicities. Pharmacodynamic studies in mice indicates that YH003 significantly increased the infiltration of anti-tumor T cells into tumors. The phase I dose escalation study carried out in Australia indicated that YH003 combined with PD-1 mAb (toripalimab) had excellent safety and antitumor activity in patients with advanced solid tumors. Currently, YH003 is undergoing phase II multi-regional clinical trials (MRCTs) for the treatment of patients with unresectable/metastatic pancreatic ductal adenocarcinoma (PDAC) and melanoma.
About Eucure Biopharma
As a wholly owned subsidiary of Biocytogen, Eucure Biopharma focuses on antibody drug therapy for oncology and other indications. Relying on a strong clinical development team with extensive experience, Eucure Biopharma develops innovative drugs to meet clinical needs for patients worldwide. The company has established a product pipeline for more than 10 targets, with two in phase II MRCTs and two in phase I clinical trials. For more information, please visit https://www.eucure.com/en/index.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMab™/RenLite® mice platforms for fully human monoclonal and bispecific antibody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. This project has resulted in 28 drug co-development agreements and 16 RenMice™ licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
About ISU ABXIS
ISU ABXIS is a biotechnology company dedicated to the development of new and novel bio-therapeutics. Founded in 2001 with the goal of developing innovative antibody-based therapeutics to treat cancer and rare diseases, for the first time in South Korea, it succeeded in developing a therapeutic antibody in 2006. ISU ABXIS has a pipeline of systematic research and management for developing treatments for intractable diseases from cancer to rare diseases, through that it has successfully developed a new drug candidate for refractory cancer and Hemophilia B, etc. Its technology advances in antibody-based platform for the treatment of human disease.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221031005767/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting samarbejder med MJB Technology Solutions om at fremme digitale transformationsmuligheder7.9.2025 08:24:00 CEST | Pressemeddelelse
Andersen Consulting styrker sin platform for digital transformation gennem et samarbejde med det canadiske firma MJB Technology Solutions, der er specialiseret i ServiceNow, kunstig intelligens, analyse og IT-transformation. MJB Technology Solutions blev stiftet i 2002 og udvikler skræddersyet software, digitale platforme og operationelle systemer til kunder inden for sektorer som banker, telekommunikation og produktion. Virksomhedens kernekompetencer omfatter komplekse ServiceNow-tjenester samt AI-baserede løsninger, business intelligence og analyse samt digital IT-strategi – og de leverer konsekvent målbare resultater og langsigtet værdi. "Gennem to årtier har vi leveret specialudviklede løsninger, der hjælper vores kunder med at tackle forretningskritiske udfordringer," siger Mark Bains, administrerende direktør hos MJB Technology Solutions. "Vores samarbejde med Andersen Consulting markerer et nyt kapitel i, hvordan vi skalerer innovation globalt, samtidig med at vi forbliver tro m
U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease6.9.2025 02:45:00 CEST | Press release
− Approval Expands Use of VONVENDI to Include Routine Prophylaxis to Reduce the Frequency of Bleeding Episodes in Adults with Type 1 and 2 Von Willebrand Disease (VWD) and On-Demand and Perioperative Management of Bleeding in Pediatric Patients with VWD1 − VONVENDI is the Only Recombinant Von Willebrand Factor Replacement Therapy with Approved Indications in Adults and Children with VWD1 − VWD, the Most Common Bleeding Disorder, Impacts More Than 3 Million People in the U.S.2 Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for VONVENDI® [von Willebrand factor (Recombinant)], expanding the indication to include routine prophylaxis to reduce the frequency of bleeding episodes in adults with von Willebrand Disease (VWD), including those with Type 1 and 2 disease, and on-demand and perioperative management of bleeding in pediatric patients with VWD. VONVENDI was previously approve
Samsung Unveils “AI Home: Future Living, Now” Vision at IFA 20255.9.2025 23:34:00 CEST | Press release
From well-being to energy efficiency, Bespoke AI, Vision AI, and Galaxy AI transform the way we live and connect. At Innovation For All (IFA) 2025, Samsung Electronics showcased its vision for “AI Home: Future Living, Now”. Samsung’s AI Home aims to be a reality people can experience today — not just in the future — and one designed for everyone, not just a select few. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250905654772/en/ Cheolgi Kim, Head of Digital Appliances, presents Future Living Now at Samsung’s IFA 2025 press conference in Berlin “At Samsung, we’re not just imagining the future of AI; we’re building it into everyday life. Samsung’s AI Home moves beyond smart devices to homes that truly understand you, adapt to your needs, and care for what matters most,” said Cheolgi Kim (CK), Executive Vice President and Head of Digital Appliances (DA) Business. “This is the beginning of a new era - where technology support
Andersen Consulting styrker end-to-end-teknologikompetencer via samarbejde med FirstQA Systems5.9.2025 19:44:00 CEST | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation og kunstig intelligens via en samarbejdsaftale med FirstQA Systems, der er en førende teknologileverandør, som er kendt for sin ekspertise inden for AI til virksomheder, digital transformation og cybersikkerhed. FirstQA Systems K.K. med hovedsæde i Japan siden 2011 er en konsulentdrevet teknologivirksomhed, der betjener Fortune 500-virksomheder og multinationale koncerner i Asien, Europa og Nordamerika. Virksomheden specialiserer sig i kunstig intelligens, digital transformation (med fokus på platformene ServiceNow, SAP og Salesforce) samt it- og OT-cybersikkerhed. Gennem sit datterselskab, Himitsu Lab Limited, leverer FirstQA Systems banebrydende Agentic AI-løsninger drevet af HIMITSU8™ Unified Development Framework (UDF)™. Virksomhedens brancheekspertise dækker bl.a. produktion, medicinalindustrien samt løsninger til bank- og finansverdenen. "Vores samarbejde med Andersen Consulting markerer et spændende sk
NetApp named a Leader by Gartner® in the 2025 Magic Quadrant™ for Enterprise Storage Platforms5.9.2025 17:15:00 CEST | Press release
Recognition reflects NetApp’s Ability to Execute and Completeness of Vision NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced it has been recognized by Gartner as a Leader in the 2025 Gartner Magic Quadrant for Enterprise Storage Platforms. NetApp believes this recognition reflects how the company’s continuous innovation helps customers build Intelligent Data Infrastructure to face modern technology challenges, including protection from cyber threats and using AI to drive data-based decisions. The evaluation was based on specific criteria that analyzed the company’s overall Completeness of Vision and Ability to Execute. According to Gartner, “Enterprise storage platforms offer platform-native service capabilities and product features for both structured and unstructured data workloads. Heads of infrastructure and operations should use this research to assess vendors in deploying a modern IT infrastructure platform for block, file and object storage.”
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom